https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct06023095-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Orforglipron Phase 1 in Chinese Obesity/Overweight Reports No Related SAEs https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct03383302-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Nivolumab with SBRT Shows Low Lung Toxicity in Early Stage NSCLC Trial https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct04624178-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Nivolumab & Rucaparib Leiomyosarcoma Trial Posts Initial Response & PFS Data https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct06370728-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Orforglipron DDI Study with Carbamazepine Posts PK Results in Healthy Adults https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct06440980-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Orforglipron PK Study in Obese/Overweight Shows Similar Capsule/Tablet Exposure https://hipa.ai/drug/pelacarsen/updates/trial-results-posted-nct05305664-2026-07-17 Hipa.ai en 2026-07-17T00:00:00.000Z Pelacarsen Lowers Apheresis Sessions by 83% in Hyperlipoproteinemia(a) https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct05086445-2026-07-16 Hipa.ai en 2026-07-16T00:00:00.000Z Orforglipron Phase 1 Trial in Type 2 Diabetes Reports Safety Profile https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05594043-2026-07-15 Hipa.ai en 2026-07-15T00:00:00.000Z Pembrolizumab Combination Phase 1 Trial in Solid Tumors Posts Safety Results https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-07-15 Hipa.ai en 2026-07-15T00:00:00.000Z Metformin Hydrochloride Label Adds Boxed Warning for Lactic Acidosis https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-glyburide-metformin-2026-07-15 Hipa.ai en 2026-07-15T00:00:00.000Z Glyburide-Metformin Hydrochloride Label Receives Lactic Acidosis Boxed Warning https://hipa.ai/drug/tofacitinib/updates/boxed-warning-revised-tofacitinib-label-effective-2026-07-15-2026-07-15 Hipa.ai en 2026-07-15T00:00:00.000Z Tofacitinib Boxed Warning Revised for Serious Infections, Mortality Risk https://hipa.ai/drug/adalimumab/updates/boxed-warning-revised-yuflyma-label-effective-2026-07-15-2026-07-15 Hipa.ai en 2026-07-15T00:00:00.000Z Yuflyma (Adalimumab) Boxed Warning Revised by FDA Effective July 15, 2026